Deals & IPOs

Therabody acquires Embr Labs’ thermal technology for women’s health

Therabody acquired Embr Labs’ thermal-wellness technology and Embr Wave intellectual property, with plans for AI-driven thermal support and expanded clinical research.

By Nathan Brooks

3 min read

Therabody Acquires Embr Labs’ Thermal Technology
Therabody Acquires Embr Labs’ Thermal Technologyfancycrave1 / pixabay

What's News

  • Therabody acquired Embr Labs’ thermal-wellness technology and related intellectual property; financial terms were not disclosed.
  • Embr Wave provides localized cooling or warming sensations at the wrist.
  • Embr Labs worked on AI capabilities intended to anticipate hot flashes and adjust thermal support.
  • The acquired technology grew from Massachusetts Institute of Technology research.
  • Dr. Rachelle Reed cited women as 50% of the population in explaining the priority.

Therabody has acquired Embr Labs’ thermal-wellness technology, including the intellectual property associated with the Embr Wave wearable. Financial terms were not disclosed.

The transaction expands Therabody’s capabilities in temperature-based wellness and women’s health, according to the companies’ announcement. Embr Labs developed Embr Wave as a wearable device that provides localized cooling or warming sensations at the wrist.

Embr Labs positioned the device as a non-drug option for people experiencing hot flashes and other forms of temperature discomfort. The company also worked on AI-driven capabilities intended to anticipate hot flashes and adjust thermal support.

What changes for women’s health?

Therabody plans to apply Embr’s research and intellectual property to a new generation of products. It will combine Embr’s work in personalized thermal stimulation with Therabody’s existing product-development, research and commercialization resources.

For consumers, the immediate change is control: Therabody now owns the acquired technology and intellectual property. The announcement did not specify launch dates, product specifications, pricing or any change in availability for Embr Wave. It also did not say whether AI-driven hot-flash prediction would ship as a standalone feature or within a broader product.

Therabody intends to continue clinical research on thermal wellness and symptoms associated with perimenopause, menopause and later stages of life. The company said women’s health will remain an important area of product development. Therabody also said it will maintain Embr’s evidence-focused approach while exploring how temperature technology can fit into a broader wellness portfolio.

The acquired technology was developed from research conducted at the Massachusetts Institute of Technology, according to the announcement. The deal therefore adds a research pipeline as well as device intellectual property. For Therabody’s product teams, the task is to convert both into next-generation offerings using its commercialization resources.

Matt Smith, CTO and Co-Founder of Embr Labs, said:

“We are thrilled that Therabody will carry our next-generation temperature technology forward. From developing the original Embr Wave to pioneering AI-driven hot flash prediction, our goal has always been about one thing: delivering real, immediate relief to the people who need it most.”

“Therabody stands at the forefront of combining rigorous science with advanced technology, and their vision for the future of wellness aligns perfectly with our own.”

Dr. Pamela Peeke, Former Chief Medical Officer of Embr Labs and Member of Therabody’s Scientific Advisory Board, said:

“Hot flashes affect most women throughout their perimenopause, menopause, and beyond. The Embr Wave was created to offer women a natural solution for controlling hot flashes and optimizing overall quality of life. I am so excited that Therabody’s team will now harness the Wave’s extraordinary promise in the development of the next-generation technology.”

“This is a game changer for women’s health.”

Dr. Rachelle Reed, Head of Scientific Research and Communication at Therabody, said:

“Women make up half of the population, so supporting their health and well-being through every stage of life is a clear priority for us. Embr has taken an evidence-first approach from the start, and that’s the standard we’ll continue to hold as we lead the next phase of clinical research and product development.”

Smith framed the handoff as an extension of Embr’s mission rather than an end to its work. Peeke, a former Embr medical chief now on Therabody’s advisory board, tied the technology to women’s health. Reed set the operating standard for the next phase: continued clinical research and evidence-focused product development.

Reed’s population figure translates the strategic case into scale: women account for 50% of the population, she said. The announcement did not include revenue forecasts, clinical-validation metrics, funding commitments or a development timetable. Those omissions leave commercial execution and clinical proof as the two tests for the deal.

The next proof point will be tangible: a disclosed clinical finding, product specification or launch date showing how the acquired research becomes a consumer product. Until one of those milestones appears, women and product teams have no new feature set, price or purchase timetable to evaluate.

Source: pulse2.com

Share this article:

More from Nathan Brooks

Nathan Brooks

Show full bio

News editor covering regulation, policy and their impact on entrepreneurship, startups and venture funding at Business Bearings.

2,473 articles

Related articles

« Previous article